Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jingjing Pu

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Stem Cell Reviews and Reports|April 23, 2026
New Gene Therapy Strategy for β-ThalassemiaDongguo Liang, Ingo G H Schmidt-Wolf, Jingjing Pu
Epigenomics|December 7, 2023
Histone deacetylase 6: at the interface of cancer and neurodegenerationJingjing Pu, Amit Sharma, Jian Hou, et al.
BMC Medical Genomics|November 18, 2023
Balancing the interplay of histone deacetylases and non-coding genomes: a step closer to understand the landscape of cancer treatmentJingjing Pu, Ting Liu, Amit Sharma, et al.
Clinical & Translational Immunology|March 26, 2024
Synergistic integration of histone deacetylase inhibitors apparently enhances the cytokine-induced killer cell efficiency in multiple myeloma via the NKG2D pathwayJingjing Pu, Amit Sharma, Ting Liu, et al.
Cancer Medicine|December 16, 2024
Balancing CIK Cell Cancer Immunotherapy and PPAR Ligands: One Potential Therapeutic Application for CNS MalignanciesKira Vordermark, JingJing Pu, Amit Sharma, et al.
European Journal of Medicinal Chemistry|July 5, 2026
Rational design and synthesis of TBC1D2 inhibitors: Augmenting autophagy to improve sorafenib sensitivity in hepatocellular carcinomaKeyan Han, Yuqi Lin, Yu Huang, et al.
Experimental Hematology & Oncology|April 23, 2024
Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectivesJingjing Pu, Ting Liu, Xuzhen Wang, et al.
Scientific Reports|January 3, 2025
Preclinical evaluation of DC-CIK cells as potentially effective immunotherapy model for the treatment of glioblastomaAnnika Simone Lück, Jingjing Pu, Ahmad Melhem, et al.
Experimental Hematology & Oncology|October 29, 2024
Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myelomaJingjing Pu, Ting Liu, Amit Sharma, et al.
Experimental Gerontology|January 8, 2024
The plasma derived exosomal miRNA-483-5p/502-5p serve as potential MCI biomarkers in agingTing Liu, Na Li, Jingjing Pu, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Stem Cell Reviews and Reports|April 23, 2026
New Gene Therapy Strategy for β-ThalassemiaDongguo Liang, Ingo G H Schmidt-Wolf, Jingjing Pu
Epigenomics|December 7, 2023
Histone deacetylase 6: at the interface of cancer and neurodegenerationJingjing Pu, Amit Sharma, Jian Hou, et al.
BMC Medical Genomics|November 18, 2023
Balancing the interplay of histone deacetylases and non-coding genomes: a step closer to understand the landscape of cancer treatmentJingjing Pu, Ting Liu, Amit Sharma, et al.
Clinical & Translational Immunology|March 26, 2024
Synergistic integration of histone deacetylase inhibitors apparently enhances the cytokine-induced killer cell efficiency in multiple myeloma via the NKG2D pathwayJingjing Pu, Amit Sharma, Ting Liu, et al.
Cancer Medicine|December 16, 2024
Balancing CIK Cell Cancer Immunotherapy and PPAR Ligands: One Potential Therapeutic Application for CNS MalignanciesKira Vordermark, JingJing Pu, Amit Sharma, et al.
European Journal of Medicinal Chemistry|July 5, 2026
Rational design and synthesis of TBC1D2 inhibitors: Augmenting autophagy to improve sorafenib sensitivity in hepatocellular carcinomaKeyan Han, Yuqi Lin, Yu Huang, et al.
Experimental Hematology & Oncology|April 23, 2024
Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectivesJingjing Pu, Ting Liu, Xuzhen Wang, et al.
Scientific Reports|January 3, 2025
Preclinical evaluation of DC-CIK cells as potentially effective immunotherapy model for the treatment of glioblastomaAnnika Simone Lück, Jingjing Pu, Ahmad Melhem, et al.
Experimental Hematology & Oncology|October 29, 2024
Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myelomaJingjing Pu, Ting Liu, Amit Sharma, et al.
Experimental Gerontology|January 8, 2024
The plasma derived exosomal miRNA-483-5p/502-5p serve as potential MCI biomarkers in agingTing Liu, Na Li, Jingjing Pu, et al.
Pageof 2